|
| Approved antiangiogenic drugs |
|
| Anti-VEGF monoclonal antibody | Indications for use |
| Bevacizumab | Metastatic colorectal cancer |
| Non-small-cell lung cancer |
| Glioblastoma multiforme |
| Metastatic renal cell cancer |
| Macular degeneration |
| Metastatic HER2 negative breast cancer |
| Persistent, recurrent, and metastatic cervical cancer |
| Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer |
|
| VEGF decoy receptor (VEGF-Trap) | Indications for use |
| Aflibercept | Metastatic colorectal cancer |
|
| Tyrosine kinase inhibitors | Indications for use |
| Sorafenib | Metastatic renal cell cancer |
| Hepatic cancer (hepatocellular carcinoma) |
| Sunitinib | Metastatic renal cell carcinoma |
| Gastrointestinal stromal tumour |
| Pancreatic neuroendocrine tumour |
| Cabozantinib | Medullary thyroid cancer |
| Erlotinib | Non-small-cell lung cancer |
| Pancreatic cancer |
| Axitinib | Metastatic renal cell cancer |
| Pegaptanib | Macular degeneration |
| Ranibizumab | Macular degeneration |
| Pazopanib | Metastatic renal cell cancer |
| Soft tissue sarcoma |
| Vandetanib | Medullary thyroid cancer |
| Regorafenib | Metastatic colorectal cancer |
| Gastrointestinal stromal tumour |
| Imatinib | Chronic myeloid leukemia |
| Renal cell cancer |
| Gastrointestinal stromal tumour |
| Dasatinib | Philadelphia chromosome-positive (Ph+) chronic |
| myeloid leukemia (CML) |
| Chronic phase Ph+ CML |
| Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (Ph+ ALL) |
|
| Mammalian target of rapamycin inhibitors (mTOR inhibitors) | Indications for use |
| Temsirolimus | Renal cell cancer |
| Everolimus | Advanced breast cancer |
| Advanced renal cell cancer |
| Pancreatic neuroendocrine tumour |
| Tuberous sclerosis complex |
| Subependymal giant cell astrocytoma |
|
